Abstract 5271
Background
Clinical trials improve our knowledge of diseases and treatments while providing patients access to investigational agents. However, approximately 3% of newly diagnosed cancer patients are enrolled in clinical trials in the United States. Identifying an appropriate trial for a patient is time-consuming and cumbersome in the busy clinical practice. The Watson for Clinical Trial Matching (CTM) cognitive system uses AI to derive patient and cancer-related attributes from structured and unstructured text found in the electronic health record. These attributes are matched to complex eligibility criteria in clinical trial protocols.
Methods
In April 2019, a pilot study was launched to test the feasibility of implementing CTM in Gastrointestinal (GI) oncology at Mayo Clinic in Rochester, MN. Two clinical research coordinators (CRCs) screened patients for potential clinical trials prior to their clinic visits using both CTM and the traditional manual screening method. To avoid bias, each CRC screened a separate set of patients by both methods alternating which methodology was used first. The clinical trial match results were blinded to both CRCs. For each method, time to complete the screen and number of potential clinical trial matches were recorded.
Results
A total of 35 GI cancer patients with new diagnosis, recent resection or restaging scans were analyzed. Patients were evaluated against 50 GI-specific drug therapy and multi-disease phase I clinical trials. Clinical trial matching using CTM took an average of 10.1 minutes (Range: 4 to 20 min) per patient compared to an average of 30.5 minutes (Range: 5 to 75 min) per patient (p < 0.0001) using the manual method. CTM identified an average of 7.66 clinical trials (Range: 0-16) while the manual screening method identified an average of 1.97 clinical trials (Range: 0 to 6) per patient (p < 0.0001).
Conclusions
Implementation of Watson for CTM system with a CRC team may enable high volume patient screening for a large number of clinical trials in an efficient manner and promote awareness of clinical trial opportunities within the GI oncology practice. Further analysis to evaluate CTM accuracy and impact on enrollment is warranted and currently underway.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Mayo Clinic.
Disclosure
T. Haddad: Advisory / Consultancy: TerSera Therapeautics; Research grant / Funding (self): Takeda. S. Coverdill: Full / Part-time employment: IBM Watson Health; Shareholder / Stockholder / Stock options: IBM. M. Rammage: Full / Part-time employment: IBM Watson Health; Licensing / Royalties: IBM. All other authors have declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract